163 related articles for article (PubMed ID: 28835741)
1. Preferences for Multiple Sclerosis Treatments: Using a Discrete-Choice Experiment to Examine Differences Across Subgroups of US Patients.
Mansfield C; Thomas N; Gebben D; Lucas M; Hauber AB
Int J MS Care; 2017; 19(4):172-183. PubMed ID: 28835741
[TBL] [Abstract][Full Text] [Related]
2. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
[TBL] [Abstract][Full Text] [Related]
3. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
4. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
[TBL] [Abstract][Full Text] [Related]
6. Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.
Kumar J; Cambron-Mellott MJ; Tencer T; Will O; Mackie DS; Beusterien K
Patient Prefer Adherence; 2021; 15():1515-1527. PubMed ID: 34267507
[TBL] [Abstract][Full Text] [Related]
7. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
Tencer T; Will O; Kumar J; Cambron-Mellott MJ; Mackie DS; Beusterien K
Curr Med Res Opin; 2021 Sep; 37(9):1589-1598. PubMed ID: 34129418
[TBL] [Abstract][Full Text] [Related]
8. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
9. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
10. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
11. An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
Visser LA; Huls SPI; Uyl-de Groot CA; de Bekker-Grob EW; Redekop WK
J Neurol Sci; 2021 Sep; 428():117587. PubMed ID: 34364148
[TBL] [Abstract][Full Text] [Related]
12. Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study.
Poulos C; Wakeford C; Kinter E; Mange B; Schenk T; Jhaveri M
Mult Scler J Exp Transl Clin; 2020; 6(1):2055217320910778. PubMed ID: 32215218
[TBL] [Abstract][Full Text] [Related]
13. Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review.
Visser LA; Louapre C; Uyl-de Groot CA; Redekop WK
Mult Scler Relat Disord; 2020 Jan; 39():101929. PubMed ID: 31924590
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
[TBL] [Abstract][Full Text] [Related]
15. Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
Feldman SR; Holmen Moeller A; Erntoft Idemyr ST; González JM
J Health Econ Outcomes Res; 2017; 4(2):141-157. PubMed ID: 37661952
[No Abstract] [Full Text] [Related]
16. Patient Preferences for Endometriosis Pain Treatments in the United States.
Poulos C; Soliman AM; Renz CL; Posner J; Agarwal SK
Value Health; 2019 Jun; 22(6):728-738. PubMed ID: 31198191
[TBL] [Abstract][Full Text] [Related]
17. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US.
Athavale A; Gooch K; Walker D; Suh M; Scaife J; Haber A; Hadker N; Dmochowski R
Patient Prefer Adherence; 2018; 12():2139-2152. PubMed ID: 30349208
[TBL] [Abstract][Full Text] [Related]
18. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
19. Patient and parent preferences for immunoglobulin treatments: a conjoint analysis.
Mohamed AF; Kilambi V; Luo MP; Iyer RG; Li-McLeod JM
J Med Econ; 2012; 15(6):1183-91. PubMed ID: 22846048
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis.
Utz KS; Hoog J; Wentrup A; Berg S; Lämmer A; Jainsch B; Waschbisch A; Lee DH; Linker RA; Schenk T
Ther Adv Neurol Disord; 2014 Nov; 7(6):263-75. PubMed ID: 25371708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
